Latest / From Our Neurons to Yours
Why new Alzheimer's drugs don't work | Mike Greicius, Stanford University School of Medicine
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.
Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.
Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.
Despite this critique, Greicius…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.